The cumulative risk of clinical failure was 8.0 % ( 95 % CI 5.6-11 .4 ) in VL versus 7.4 % ( 5.1-10 .7 ) in CD4 , and the upper-limit of the one-sided 95 % CI of the difference was 3.4 % , meeting the pre-determined non-inferiority criterion .
